Mission Driven, Interdiscipinary Teams
1
Mission
3
QA certifications
8+
Countries represented
20,000+
Hours of R&D
We were founded with two core questions: Why, despite significant scientific advances, are only two treatments approved for hair loss? And can we deliver solutions that translate modern research directly into patient care?
With both our co-founders Dr Nicholas Sadgrove and David Barreto experiencing this type of hair loss, our mission was singular: to enhance outcomes for those suffering from chronic and progressive hair loss that affects most hair transplant patients. We continuously push for improvements in every product aspect—from understanding the mechanisms of hair health to ensuring ingredient purity, bioavailability, and targeted follicle action. With four years of iterative development, we’ve crafted a technology that delivers radically better results for patients.
The status quo has failed patients
Despite the prevalence of hair loss, only two treatments—minoxidil and finasteride—have been approved, both developed several decades ago. These options give highly limited long-term results and bring widespread safety concerns respectively, yet they remain the default.
On the other hand, many non-drug treatments lack rigorous testing, often relying on subjective measures like “self-assessed hair thinning” that excludes patients with the most common chronic and progressive hair loss. Harvard dermatologist Dr. Senna has highlighted the predatory tactics in this industry, which can breed unrealistic expectations in non-target patients and fuel skepticism about non-drug solutions. Thus, any company entering this category will by default fight an uphill battle to overcome the mottled reputation that surrounds it.
80 million affected in US
80 years of research
2 outdated drugs approved
0 approvals since 1997
Exponential Research Growth
Green: peer-reviewed publications for androgenetic alopecia since 1997. Source: PubMed
While commercial options for hair loss have stalled, scientific understanding has surged—and Systems Trichology London is bringing this progress directly to patients.
The “DHT paradox” exemplifies this: while DHT stimulates hair growth on most of the body, it damages scalp hair, likely through the action of TGF-β1, which promotes follicle miniaturization in high-DHT environments. Emerging research shows TGF-β1 inhibitors can significantly increase hair density. Metabolic health is another critical factor. In 2018,
Dr. Nicholas Sadgrove linked hyperglycemia to hair loss, and recent studies confirm a 57% higher incidence of hair loss in men consuming sugary drinks, with type 2 diabetes showing similar impacts in women. Our work is the first to clarify how metabolic stress accelerates hair loss. Intimately involved in energy metabolism, new insights into mitochondrial health show that damaged mitochondria contribute to balding scalps. While low-level laser therapy boosts mitochondrial function and ATP in hair follicles, we asked, could there be pharmacological methods to improve their function?
We’re transforming these scientific advancements into meaningful improvements for those affected by hair loss.